Logo image of ARCT

ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Fundamental Analysis

NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD

12.38  -0.26 (-2.06%)

After market: 12.38 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ARCT. ARCT was compared to 557 industry peers in the Biotechnology industry. While ARCT seems to be doing ok healthwise, there are quite some concerns on its profitability. ARCT is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARCT had negative earnings in the past year.
In the past year ARCT has reported a negative cash flow from operations.
In the past 5 years ARCT reported 4 times negative net income.
In the past 5 years ARCT reported 4 times negative operating cash flow.
ARCT Yearly Net Income VS EBIT VS OCF VS FCFARCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of ARCT (-20.56%) is better than 77.82% of its industry peers.
With a decent Return On Equity value of -29.18%, ARCT is doing good in the industry, outperforming 79.07% of the companies in the same industry.
Industry RankSector Rank
ROA -20.56%
ROE -29.18%
ROIC N/A
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ARCT Yearly ROA, ROE, ROICARCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCT Yearly Profit, Operating, Gross MarginsARCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARCT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARCT has more shares outstanding
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARCT Yearly Shares OutstandingARCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ARCT Yearly Total Debt VS Total AssetsARCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.55, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
ARCT has a better Altman-Z score (0.55) than 65.83% of its industry peers.
ARCT has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.06, ARCT is doing worse than 63.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 0.55
ROIC/WACCN/A
WACC9.05%
ARCT Yearly LT Debt VS Equity VS FCFARCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ARCT has a Current Ratio of 5.64. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.64, ARCT perfoms like the industry average, outperforming 58.32% of the companies in the same industry.
A Quick Ratio of 5.64 indicates that ARCT has no problem at all paying its short term obligations.
ARCT's Quick ratio of 5.64 is in line compared to the rest of the industry. ARCT outperforms 59.39% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 5.64
ARCT Yearly Current Assets VS Current LiabilitesARCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.29% over the past year.
ARCT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.44%.
Measured over the past years, ARCT shows a very strong growth in Revenue. The Revenue has been growing by 48.91% on average per year.
EPS 1Y (TTM)35.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
Revenue 1Y (TTM)15.44%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-22.7%

3.2 Future

Based on estimates for the next years, ARCT will show a very strong growth in Earnings Per Share. The EPS will grow by 37.85% on average per year.
ARCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.16% yearly.
EPS Next Y-24.4%
EPS Next 2Y-0.18%
EPS Next 3Y23.72%
EPS Next 5Y37.85%
Revenue Next Year-42.67%
Revenue Next 2Y-10.63%
Revenue Next 3Y11.18%
Revenue Next 5Y28.16%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARCT Yearly Revenue VS EstimatesARCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ARCT Yearly EPS VS EstimatesARCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCT Price Earnings VS Forward Price EarningsARCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCT Per share dataARCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

ARCT's earnings are expected to grow with 23.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.18%
EPS Next 3Y23.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCTURUS THERAPEUTICS HOLDIN

NASDAQ:ARCT (6/13/2025, 7:35:43 PM)

After market: 12.38 0 (0%)

12.38

-0.26 (-2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners92.25%
Inst Owner Change-0.3%
Ins Owners0.81%
Ins Owner Change0%
Market Cap335.75M
Analysts86.67
Price Target59.99 (384.57%)
Short Float %21.67%
Short Ratio12.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.26%
Min EPS beat(2)-98.22%
Max EPS beat(2)61.7%
EPS beat(4)3
Avg EPS beat(4)25.82%
Min EPS beat(4)-98.22%
Max EPS beat(4)79.04%
EPS beat(8)6
Avg EPS beat(8)-70.91%
EPS beat(12)10
Avg EPS beat(12)235.89%
EPS beat(16)12
Avg EPS beat(16)174.63%
Revenue beat(2)1
Avg Revenue beat(2)-20.17%
Min Revenue beat(2)-50.01%
Max Revenue beat(2)9.67%
Revenue beat(4)3
Avg Revenue beat(4)24.15%
Min Revenue beat(4)-50.01%
Max Revenue beat(4)125.3%
Revenue beat(8)5
Avg Revenue beat(8)37.16%
Revenue beat(12)9
Avg Revenue beat(12)164.58%
Revenue beat(16)9
Avg Revenue beat(16)111.88%
PT rev (1m)-5.44%
PT rev (3m)-12.47%
EPS NQ rev (1m)10.56%
EPS NQ rev (3m)20.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-70.79%
Revenue NQ rev (1m)3%
Revenue NQ rev (3m)-64.05%
Revenue NY rev (1m)-5.08%
Revenue NY rev (3m)-42.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.34
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-2.53
EYN/A
EPS(NY)-3.02
Fwd EYN/A
FCF(TTM)-3.31
FCFYN/A
OCF(TTM)-3.29
OCFYN/A
SpS5.3
BVpS8.62
TBVpS8.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.56%
ROE -29.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.84%
Cap/Sales 0.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.64
Quick Ratio 5.64
Altman-Z 0.55
F-Score4
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)207.21%
Cap/Depr(5y)221.18%
Cap/Sales(3y)1.97%
Cap/Sales(5y)10.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
EPS Next Y-24.4%
EPS Next 2Y-0.18%
EPS Next 3Y23.72%
EPS Next 5Y37.85%
Revenue 1Y (TTM)15.44%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-22.7%
Revenue Next Year-42.67%
Revenue Next 2Y-10.63%
Revenue Next 3Y11.18%
Revenue Next 5Y28.16%
EBIT growth 1Y33.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-61.13%
EBIT Next 3Y-0.84%
EBIT Next 5YN/A
FCF growth 1Y-331.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-297.8%
OCF growth 3YN/A
OCF growth 5YN/A